2025-01-15 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Analysis Report

**1. Performance Comparison & Overview:**

Colgate-Palmolive Co (CL) is a consumer goods company that manufactures and sells oral hygiene products, personal care products, and pet nutrition products worldwide.

Compared to the S&P 500 (VOO), CL significantly underperformed.  The cumulative return for CL is 33.99%, while VOO shows a cumulative return of 112.74%. The difference is -78.8%, placing it at the 5.4th percentile of its historical relative performance against VOO (based on the provided min/max range). This indicates substantial underperformance compared to the broader market.  The provided alpha values consistently show positive returns above the market (Beta of ~0.2), but this is offset by lower overall returns.

**2. Recent Price Movement:**

* **Closing Price:** $87.67
* **5-Day Moving Average:** $87.20
* **20-Day Moving Average:** $90.60
* **60-Day Moving Average:** $93.41

The price is below all three moving averages, suggesting a downward trend.  The stock is trading at a discount to its recent average prices.

**3. Technical Indicators & Expected Return:**

* **RSI (23.79):** This indicates the stock is in oversold territory, suggesting potential for a price bounce.
* **PPO (-0.38):**  A negative PPO suggests bearish momentum.
* **Relative Strength (20-Day):** +5.4. While showing short-term strength, this doesn't offset the broader underperformance against the market.
* **Expected Return (-819.9%):** This extremely negative expected return figure is concerning and needs clarification.  Such a dramatic negative projection likely requires further investigation into its calculation methodology. The provided data might include an error in calculation, or the measure might be comparing specific time horizons.
* **Price Consideration:**  The current price of $87.67 is not explicitly indicative of a dramatic event (like a sudden crash) based only on this data point.  However, the other indicators suggest the stock is currently underperforming.

**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue      |
|------------|---------|--------------|
| 2024-10-25 | $0.90   | $5.03B       |
| 2024-07-26 | $0.89   | $5.06B       |
| 2024-04-26 | $0.83   | $5.07B       |
| 2023-10-27 | $0.86   | $4.92B       |
| 2024-10-25 | $0.86   | $4.92B       | *(Duplicate entry - likely a data error)*


There appears to be a data duplication error in the October 2024 entry.  Revenue has remained relatively stable, with minor fluctuations, while EPS shows a slight upward trend.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $5.03B | 61.08%       |
| 2024-06-30 | $5.06B | 60.62%       |
| 2024-03-31 | $5.07B | 60.00%       |
| 2023-12-31 | $4.95B | 59.60%       |
| 2023-09-30 | $4.92B | 58.54%       |

Revenue is relatively consistent, and profit margins are high and have shown slight improvement.

**Capital and Profitability:**

| Quarter | Equity   | ROE          |
|---------|----------|---------------|
| 2024-09-30 | $0.43B  | 169.43%      |
| 2024-06-30 | $0.12B  | 594.31%      |
| 2024-03-31 | $0.23B  | 296.96%      |
| 2023-12-31 | $0.61B  | 117.90%      |
| 2023-09-30 | -$0.01B | -7866.67%     |

ROE shows significant volatility, with a large negative value in Q3 2023, requiring further investigation to understand the underlying reasons for this extreme fluctuation.  Further information beyond these figures is needed for proper analysis.


**7. Overall Analysis:**

CL currently shows significant underperformance compared to the S&P 500, despite relatively stable revenue and high profit margins. The extremely negative projected return needs further clarification, and the volatile ROE figures require investigation. While the RSI suggests oversold conditions, the negative PPO and price being below its moving averages point to a bearish trend.  A more thorough analysis is required, especially regarding the outliers in ROE and the highly negative expected return, before making any investment decisions.  The data provided contains inconsistencies that needs to be addressed before drawing further conclusions.  Consult financial statements and professional advice before making any investment decisions.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  The analysis is based on the limited data provided and may not reflect the full picture.  Conduct thorough due diligence and consult with a qualified financial advisor before making any investment decisions.
